Coronary lithoplasty for calcified lesions: real-world multicenter registry

Héctor Cubero-Gallego, a Raúl Millán, b Mónica Fuertes, c Ignacio Amat-Santos, d Xavier Quiroga, b Josep Gómez-Lara, c Neus Salvatella, b Helena Tizón-Marcos, b,f Alejandro Negrete, f Sandra Santos-Martínez, d Mohsen Mohandes, g Joan A. Gómez-Hospital, g César Morís, a and Beatriz Vaquerizo b,f,*

a Área del Corazón, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias-ISP, Universidad de Oviedo, Oviedo, Asturias, Spain
b Unidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital del Mar, Universidad Autónoma de Barcelona, Barcelona, Spain
c Unidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital Universitario Joan XXIII, Universidad Rovira y Virgili, Tarragona, Spain
d Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares-CIBERCV, Instituto de Ciencias del Corazón-ICICOR, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
e Unidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital Universitario de Bellvitge, Instituto de Investigación Biomédica de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
f Unidad Hospital del Mar de Investigaciones Médicas-IMIM, Barcelona, Spain

Original article

ABSTRACT

Introduction and objectives: Coronary lithoplasty (CL) is a balloon-based technique used to treat calcified lesions. This study reports the initial experience of treatment of calcified lesions with CL in an unselected and high-risk population.

Methods: This was a prospective, multicenter registry, which included all consecutive cases with calcified coronary lesions that underwent CL between August, 2018 and August, 2019. Exclusion criteria consisted of a target lesion located in a small vessel (< 2.5 mm) and the presence of dissection prior to CL. Quantitative coronary angiography and intravascular ultrasound/optical coherence tomography analysis were completed by an independent central core laboratory.

Results: This registry included 57 patients (66 lesions). The population was elderly (72.6 ± 9.4 years) with high proportions of patients with diabetes (56%), chronic kidney disease (35%), and multivessel disease (84%). All lesions were classified as type B/C. More than 75% of lesions were predilated with noncompliant/semicompliant balloons or cutting-balloon. Rotablator was used in 5 lesions (7.6%) prelithoplasty. On average, CL required 1.17 balloons delivering a mean of 60 pulses. Successful CL was achieved in 98%. In 13% of cases, lithoplasty balloon was broken during therapy. There were few procedural complications: 2 cases of significant dissections (none related to lithoplasty balloon rupture) were successfully treated with drug-eluting stent implantation. One patient experienced stent thrombosis 2 days after successfully undergoing target lesion revascularization.

Conclusions: This is a real-world multicenter registry, which supports the feasibility, safety, and short-term efficacy of PCI for calcified coronary lesions using CL in an unselected and high-risk population with promising results.

© 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Litoplastia coronaria en lesiones calcificadas: registro multicéntrico de la práctica clínica

RESUMEN

Introducción y objetivos: La litoplastia coronaria (LC) es una técnica con balón que se utiliza para tratar lesiones calcificadas graves. Este estudio describe la experiencia inicial del tratamiento de lesiones calcificadas con LC en una población no seleccionada y de alto riesgo.

Métodos: Registro prospectivo, multicéntrico, que incluyó consecutivamente todos los casos con lesiones coronarias calcificadas que se trataron con LC entre agosto de 2018 y agosto de 2019. Los criterios de exclusión fueron lesiones localizadas en vaso pequeño (< 2.5 mm) y la presencia de diseción previa a la LC. Un laboratorio central independiente realizó la angiografía coronaria cuantitativa y el análisis de la ecocardiografía intravascular/tomografía de coherencia óptica.

Resultados: Este registro incluyó a 57 pacientes (66 lesiones). Una población de edad avanzada (72.6 ± 9.4 años) con alta proporción de pacientes diabéticos (56%), enfermedad renal crónica (35%) y
INTRODUCTION

Calculated coronary lesions (CCL) are challenging to treat with percutaneous coronary intervention (PCI). Population aging and growing prevalences of diabetes mellitus and chronic kidney disease are associated with an increase in coronary calcification. The severity of endoluminal calcium may be underestimated by coronary angiography or fluoroscopy, so intravascular imaging techniques, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), are required to achieve a meticulous assessment of the severity and characterization of the lesion.

Severe coronary calcium increases PCI complexity. It may impair the crossing of the lesion, affect suitable stent expansion and apposition, damage the drug-eluting polymer, increase the risk of stent thrombosis and restenosis, and adversely impact acute and long-term results after PCI. The optimal approach to the treatment of CCL requires knowledge of several factors: lesion characteristics, calcium distribution, intravascular imaging techniques, and the mechanism of each plaque-modification device.

Available techniques for the treatment of CCL can be divided into 2 groups: nonballoon and balloon-based technologies. Plaque-modification techniques include nonballoon technologies such as rotational atherectomy (RA), orbital atherectomy, and excimer laser. Balloon-based technology may increase the lumen diameter by cracking the calcium circumferentially and allowing greater elasticity of the lesion.

We recently described the successful initial experience with coronary lithoplasty (CL) for modification of CCL in a series of 3 cases. CL is a new technique: it involves the use of high-energy mechanical pulses, delivered by a semipliant balloon, to crack coronary calcium. The lithoplasty balloon (LB) is inflated at a pressure of 4 atm in the target calcified lesion and delivers pulsatile mechanical waves at a frequency of 1 Hz. The mechanical energy is transmitted to the lesion when the LB contacts the intima layer, allowing the fracture of calcium in the superficial and deeper coronary wall layers. These shockwaves allow adequate plaque modification and suitable stent expansion and apposition.

CL is a simple technique with a short learning curve and promising initial results. It seems to have more effect on deep calcium than other plaque-modification techniques; therefore, it may become a standard approach for treating CCL. Despite successful early results in select coronary lesions, there are few real-world data published about the use of CL. Its safety and possible procedural complications remain unclear, and the effects of combination with other plaque-modification devices are unknown. The objective of this study was to provide further insight about the safety and efficacy of CL for the treatment of CCL, by reporting the initial outcomes of the CL by analyzing a real-world multicenter registry.

METHODS

Study design and study population

This registry was a prospective, multicenter, single-arm study in which from August 2018 until August 2019, 57 consecutive patients with 66 calcified coronary lesions treated with the Coronary Rx Lithoplasty System (Shockwave Medical, Inc, United States) were included, following the intention-to-treat principle.

This study was conducted at 5 hospitals in a single country. All centers participated on a voluntary and unaudited basis. Eligible patients were older than 18 years with stable angina or acute coronary syndrome suitable for PCI and had CCL with significant stenosis (>50% diameter stenosis) and a vessel diameter ≥2.5 mm assessed by visual estimation and quantitative coronary angiography. The exclusion criteria in this real-world registry consisted of a target lesion located in a small vessel (<2.5 mm) and the presence of significant (more than type B) coronary dissection prior to CL.

Quantitative coronary angiography was completed by an independent central core laboratory (BARCICORE Lab, Spain). The analysis was performed using dedicated coronary angiography analysis software (CAAS version 5.9, Pie Medical BV, the Netherlands). OCT data were also analyzed at the same core laboratory (BARCICORE Lab, Spain) by experienced analysts, who were also blinded to the clinical data, using proprietary offline software (LightLab Imaging, St Jude Medical Inc, United States).

This study was performed according to the provisions of the Declaration of Helsinki, ISO 14153, and clinical practice guidelines. The study protocol was approved by the Institutional Ethics Committee and the hospital’s research commission. Written informed consent was obtained from all patients.

Study endpoints and definitions

The main objectives of this study were to provide further insight about the safety and efficacy of CL for the treatment of CCL.
and to report short-term clinical outcomes in a very high-risk population. Clinical and angiographic endpoints were defined according to the recommendations of the Academic Research Consortium.\textsuperscript{13} Academic Research Consortium represents a step toward standardization, facilitating the evaluation of the safety and effectiveness of devices.

Lithoplasty success was defined as achievement of < 50% of residual diameter stenosis of the target lesion as assessed by visual inspection or quantitative coronary angiography, as well as successful deployment of the stent.

Bleeding as a safety endpoint was defined according to the Bleeding Academic Research Consortium.\textsuperscript{14} Major bleeding was defined as Bleeding Academic Research Consortium types 3 and 5.

**Lithoplasty system and procedural characteristics**

All lesions were treated with the Coronary Rx Lithoplasty System (Shockwave Medical, Inc). The LB is a single-use angioplasty balloon catheter with a length of 12 mm and available diameters ranging from 2.5 mm to 4 mm; it is advanced over a 0.014 inch guidewire. The LB emits acoustic circumferential pressure pulses, which allows the treatment of concentric calcified lesions (figure 1). CL allows the safe treatment of bifurcation lesions since the side-branch can be protected during the procedure. The concomitant use and order of other plaque-modification devices, such as RA and/or cutting/scoring balloon, as well as regular and special balloons (eg, semicompliant balloon, noncompliant balloon, and double-twin high-pressure balloon), were performed at the discretion of the operator. When lesion tortuosity was moderate to severe, special devices, such as guide extension catheters, were recommended.

Each procedure was performed via radial, femoral, or humeral access with a guide catheter ≥ 6 Fr. The LB was placed in the target lesion and connected to an external unit to generate pulsatile mechanical waves (figure 1). The ratio of the size of the LB to the coronary artery was 1:1. The LB was initially inflated to a pressure of 4 atm and delivered 1 therapy of 10 pulses (requiring approximately 10 seconds). Then, the LB was inflated to a pressure of 6 atm and a total of 3 to 8 therapies (up to 80 pulses) per balloon and per lesion was delivered, with intervals of deflation to allow distal perfusion. The use of the LB is simple and requires a short learning curve, which simplifies the PCI procedure.

Due to the size of the LB, if the lesion length was > 12 mm, the LB was repositioned to treat the total calcified lesion. Implantation of a drug-eluting stent was performed at the discretion of the operator. Dual antiplatelet therapy was also left to the operator’s discretion and initiated according to recommendations for standard of care.

**Statistical analysis**

Statistical analysis was performed using STATA software version 15.0 (StataCorp, Tx, United States). Continuous variables are shown as mean ± standard deviation (SD) or median with interquartile range [IQR]. Categorical variables are expressed as frequencies and group percentages.

**RESULTS**

From August 2018 to August 2019, 57 patients (66 lesions) with CCL assessed by angiography were enrolled in the study. All lesions were treated with the Coronary Rx Lithoplasty System (Shockwave Medical, Inc). Baseline clinical, lesion, and procedural characteristics are listed in table 1, table 2, table 3, table 4, and table 5. As shown in table 1 and table 2, the study included a relatively elderly population (mean age, 72.6 ± 9.4 years old), and high proportions of patients had diabetes (56%), and chronic kidney disease (35%). A significant percentage of patients had existing coronary heart disease (65%) and previous revascularization (44%). Most of patients also had multivessel disease (84%), and the population had a mean SYNTAX score of 23. The most frequently treated artery was the left anterior descending artery. CL was used in 30 bifurcated lesions (45%) and lateral branch protection was performed in 19 lesions (63% of the bifurcated lesions). LB was used in 8 left main coronary artery lesions. Five patients with ST-segment elevation myocardial infarction underwent CL; thromboaspiration was performed when thrombus was objectified after guidewire passage. LB was used in all cases without the presence of macroscopic thrombus.

All lesions were classified as type B (39%) or C (61%) according to the American College of Cardiology/American Heart Association classification. Moreover, lesions were considered as significant calcified lesions and most of the calcium distribution was eccentric (68%). Intravascular imaging techniques (IVUS/OCT) were performed at the discretion of the operator in more than half of the patients, but only 16 cases showed minimum criteria for proper analysis to be analyzed (table 5 and figure 2).

Procedural characteristics are listed in table 3. Multivessel revascularization was performed in 30% of patients. In more than half of the patients, vascular access was radial. More than 75% of lesions were predilated. It is notable that the concomitant use of other plaque-modification devices before LB was found to be safe. RA was used before the LB in 5 cases and cutting/scoring balloons were used before the LB in 16 cases. Despite use of the
second generation of the device, which has improved its navigation profile to be more effective in the presence of tortuosity, in 11 cases (16.7%) a catheter extender was needed due to lesion tortuosity to place the LB at the level of the lesion.

On average, coronary lithotripsy was achieved by the use of 1 balloon [range, 1–2] delivering 3 therapies [range, 2.5–4] with a mean of 60 pulses and a total mean inflation time of 64 seconds. Nine (13%) LB were broken during therapy without any dissection related to the rupture; the mean number of cycles before rupture was 3 [range, 2.5–4]. In cases where the LB was broken, the lesions had no specific characteristics, such as increased eccentricity, that could be related to the therapy.

Successful CL was achieved in 98% of cases. There was only 1 case in which it was not possible to achieve < 50% of residual diameter stenosis of the target lesion after noncompliant balloon and cutting-balloon preCL; in this case, 2 LBs were applied with a total of 160 pulses, as well as 1 double-twin-layer balloon. Thus, this patient was treated with a drug-eluting balloon. The average number of stents per lesion was 1 [range, 1–2] according to lesion length and the treatment of residual stent edge dissection. Mean stent diameter was 3.3 ± 0.9 mm and total mean stent length was 26.7 ± 9.3 mm.

Quantitative angiographic characteristics

Angiographic characteristics are shown in Table 4. Quantitative coronary angiography was adequately performed on 61 lesions before and after the procedure (5 cases did not show enough quality for the correct analysis). The mean reference vessel diameter was 2.8 ± 0.5 mm and lesion length was 26 ± 10.4 mm (Figure 1 of the supplementary data).


**Table 3**

Procedural characteristics (57 patients and 66 lesions)

<table>
<thead>
<tr>
<th>Number of patients (n=57)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multivessel revascularization</td>
</tr>
<tr>
<td>Vascular access</td>
</tr>
<tr>
<td>Radial</td>
</tr>
<tr>
<td>Femoral</td>
</tr>
<tr>
<td>Humeral</td>
</tr>
<tr>
<td>Fluoroscopy duration, min</td>
</tr>
<tr>
<td>Total contrast volume, ml</td>
</tr>
</tbody>
</table>

**Table 4**

Quantitative angiographic analysis of lesions treated (n=61)

<table>
<thead>
<tr>
<th>Coronary lithoplasty lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before procedure</td>
</tr>
<tr>
<td>RVD, mm</td>
</tr>
<tr>
<td>MLD, mm</td>
</tr>
<tr>
<td>Diameter stenosis, %</td>
</tr>
<tr>
<td>After procedure</td>
</tr>
<tr>
<td>RVD, mm</td>
</tr>
<tr>
<td>In-stent</td>
</tr>
<tr>
<td>In-segment</td>
</tr>
<tr>
<td>Diameter stenosis, %</td>
</tr>
<tr>
<td>In-stent</td>
</tr>
<tr>
<td>Stent length, mm</td>
</tr>
<tr>
<td>Acute gain, mm</td>
</tr>
<tr>
<td>In-stent</td>
</tr>
</tbody>
</table>

MLD: minimum vessel diameter; RVD: reference vessel diameter. Values are expressed as mean ± standard deviation.

**Table 5**

Intravascular imaging results (n=16)

<table>
<thead>
<tr>
<th>Coronary lithoplasty lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intravascular ultrasound</td>
</tr>
<tr>
<td>Optical coherence tomography</td>
</tr>
<tr>
<td>Matched segment length (stent length), mm</td>
</tr>
</tbody>
</table>

**DISCUSSION**

This is the largest real-world registry to demonstrate the feasibility, safety, and short-term efficacy of PCI for severely calcified lesions using coronary lithotripsy in an unselected and high-risk population. There are some interesting findings of this study. First, compared with historical stent registries of plaque modification for CCL, the rate of procedural complications in this registry was remarkably low. Second, LB seems to be effective for calcium rupture and facilitates stent delivery and expansion. Last, the present study is the first to demonstrate the safety of the concomitant use of other plaque-modifications devices with CL.

The use of lithoplasty balloon in calcified lesions and procedural complications

In calcified lesions, current plaque-modification techniques have been associated with a relatively high procedural complication rate. Complications of RA include coronary dissection, perforation, burr lodging, and slow-flow/no-reflow phenomenon. The perforation rate with rotablator varies, but nears 1%, and orbital atherectomy has a perforation rate up to 2%. Our results show a remarkably low rate of procedural complications. There were 2 dissections due to CL, but none related to the LB rupture. In our opinion, the breakage of LB seems to occur during the emission of high-energy mechanical pulses rather than during the inflation. This fact may be due to the resistance of the LB to the
therapy, since in some cases there would not be rupture of the LB but rather micro-fissures or an increased porosity, which could lead to the loss of pressure. Rotablator and orbital atherectomy generate microparticles, which may be embolized distally during the procedure causing slow-flow/no-reflow: the incidence is up to 3% with rotablator.\textsuperscript{13,16} However, calcium fragments, which are generated by LB, seem to remain in situ.\textsuperscript{10} Accordingly, in our study, there were no slow-flow/no-reflow events. Although this may be purely fortuitous, we believe it can be at least partially explained by the mechanism of this novel “special” balloon device, which seems to crack calcium circumferentially, increasing lesion compliance and facilitating stent delivery and expansion.\textsuperscript{10,11}

Promising 1-month results

Severe coronary calcification is a strong predictor of major adverse cardiovascular events (MACE) after PCI.\textsuperscript{1} Established plaque-modification techniques have shown a high MACE rate at follow-up.\textsuperscript{10,17} The ORBIT II study,\textsuperscript{17} which included 443 patients who underwent orbital atherectomy followed by stenting, showed a MACE rate of 10% at the 30-day follow-up. Our registry showed a MACE rate of 3.5% at the 30-day follow-up.

Despite the small numbers and the heterogeneous, high-risk population, our short-term results are promising and comparable to those achieved with noncalcified lesions. Our results, therefore, complement the findings of the much more selective studies using LB. The DISRUPT CAD I trial demonstrated the safety and performance of coronary lithotripsy in CCL prior to stenting with a MACE rate of 3% at the 30-day follow-up.\textsuperscript{14} The DISRUPT CAD II study, with 120 patients, demonstrated the safety of CL before stent implantation with a 30-day MACE rate of 7.6%.\textsuperscript{19} Currently, a large trial is being conducted to assess the safety and effectiveness of CL and confirm these promising results: DISRUPT CAD III with approximately 392 patients.

User-friendly plaque-modification device

CL is a new and simple technique with a short learning curve compared with other plaque-modifications devices.\textsuperscript{11,20} Our study is the first to demonstrate the safety of the concomitant use of other plaque-modifications devices, including RA. In this high-risk
population, most patients were not considered candidates for coronary artery bypass graft.

The second-generation LB showed a better crossing profile than expected for a balloon angioplasty catheter with emitters. In our registry, complex lesions (type B or C) were successfully treated despite severe calcification and eccentric calcium distribution. If moderate-to-severe tortuosity was present, LB showed feasibility with the concomitant use of a guide extension catheter.

In agreement with our initial experience and a recent case report, LB seems to facilitate expansion of in-stent restenosis due to an underexpanded stent, showing that stent struts may not impede the transmission of shockwaves to the vessel wall.\textsuperscript{21,22} Initial results of treating severe calcified lesions in the left main coronary artery with left ventricular dysfunction have been reported.\textsuperscript{23,24} Our registry included the safe and successful treatment of 8 severe calcified lesions in the left main artery with CL. The first experience with CL for the treatment of CCL in patients with ST-segment elevation myocardial infarction has been reported.\textsuperscript{25} Our registry included the successful treatment of 5 patients with ST-segment elevation myocardial infarction and severe calcified lesions with CL.

Some interesting technical tips should be highlighted. CL may be effective in large vessels, since LB are available in diameters up to 4 mm, which is larger than rotablator burrs and orbital crowns. LB may also be a feasible treatment for bifurcated lesions since it allows the placement of 2 wires during the procedure. Intravascular imaging techniques should be performed for CL guidance and to achieve optimal PCI results; our study showed 1 stent thrombosis caused by stent malapposition, which may have been avoided by performing OCT.

Limitations

This was an observational study, not a randomized controlled study. The sample size was relatively small, with a short follow-up time, absence of a comparison group, with heterogeneity of lesions included and with self-reporting of events. However, larger registries with longer follow-up periods are needed to investigate the use of CL and to assess future randomized studies comparing CL in severe calcified lesions to standard treatment. It is important to understand the effect of prolonged balloon inflation related to silent ischemia and the effect of delivering intermittent high-pressure pulses on vessel walls in terms of inflammation and stent restenosis in long-term follow-up. Additionally, despite the rupture of LB, the procedure seems to be safe, although rupture is unpredictable and always occurs while applying the therapy, which requires the use of another LB and increases the cost. Finally, routine pre- and postintervention IVUS/OCT were not performed to predefine inclusion parameters or to confirm optimal stent results.

CONCLUSIONS

This is a real-world multicenter registry, which supports the feasibility, safety, and short-term efficacy of PCI for calcified lesions using CL in an unselected and high-risk population with promising results. In addition, the present study is the first to demonstrate the safety of the concomitant use of other plaque-modification devices with LB. Larger multicenter registries with long-term follow-up are required to clarify the role of plaque modification using CL.

CONFLICTS OF INTEREST

All the authors state that there are no potential conflicts of interest related to this work.

WHAT IS KNOWN ABOUT THE TOPIC?

- Severe coronary calcium increases the complexity of percutaneous revascularization. Available techniques for the treatment of severe calcified lesions can be classified as nonballoon technology (rotablator, orbital atherectomy, and excimer laser) or balloon-based technology (CL).
- Coronary lithotripsy is a simple technique with a short learning curve: it may increase lumen diameter and lesion compliance. Despite successful early results in select coronary lesions, there are few real-world data published about coronary lithotripsy, and its safety and possible procedural complications remain unclear.

WHAT DOES THIS STUDY ADD?

- This is a real-world multicenter registry, which supports the feasibility, safety, and short-term efficacy of CL for calcified lesions in an unselected and high-risk population.
- This study is the first to demonstrate the safety of the concomitant use of other plaque-modification devices with CL. A LB is a user-friendly device, which seems to be safe and effective for complex lesions, and has a remarkably low rate of procedural complications.
REFERENCES


